Dec. 11 at 12:57 PM
$OCUL The only near-term (6 months +/-) negative I see (besides dubious CT Results for SOL-1)for
$OCUL is if
$EYPT gets bought-out by a heavy-hitter (Regeneron, Merck, Bausch, etc.) and Ocular *goes it alone*.
CEO Dugel, who was coaxed ($$$) out of *retirement* to take the role at OCUL and the BOD/INSTI's don't seem to be the type to want to slog through a commercial turf war, though....especially, alone.
